| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00262-017-2080-1 |
| P698 | PubMed publication ID | 29051990 |
| P50 | author | Ming-Xiang Zou | Q50988208 |
| P2093 | author name string | Jing Li | |
| Wei Huang | |||
| Yi Jiang | |||
| Guo-Hua Lv | |||
| Xiao-Bin Wang | |||
| Xiao-Ling She | |||
| Ke-Miao Guo | |||
| P2860 | cites work | Cancer classification using the Immunoscore: a worldwide task force | Q21245495 |
| Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade | Q24535835 | ||
| Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method | Q25938999 | ||
| Tumor-intrinsic oncogene pathways mediating immune avoidance | Q26747707 | ||
| Innate and adaptive immune cells in the tumor microenvironment | Q27008342 | ||
| MicroRNAs: genomics, biogenesis, mechanism, and function | Q27861070 | ||
| PD-L1 and Survival in Solid Tumors: A Meta-Analysis | Q28084090 | ||
| Type, density, and location of immune cells within human colorectal tumors predict clinical outcome | Q28131662 | ||
| Chordoma: current concepts, management, and future directions | Q28258811 | ||
| Cancer statistics, 2007 | Q29547293 | ||
| Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer | Q29615679 | ||
| Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma | Q30278895 | ||
| Chordoma: incidence and survival patterns in the United States, 1973-1995. | Q33270957 | ||
| Chordoma: natural history and results in 28 patients treated at a single institution. | Q33271347 | ||
| Expression of MDR1, HIF-1α and MRP1 in sacral chordoma and chordoma cell line CM-319 | Q33274001 | ||
| Novel therapeutic targets in chordoma | Q33274528 | ||
| Expression of insulin-like growth factor II mRNA-binding protein 3 (IMP3) in sacral chordoma | Q33274978 | ||
| Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis | Q33275157 | ||
| A review of the surgical management of sacral chordoma | Q33275250 | ||
| Clinical features and prognostic factors of patients with chordoma in the spine: a retrospective analysis of 153 patients in a single center | Q33275464 | ||
| Reduced expression of miRNA-1237-3p associated with poor survival of spinal chordoma patients | Q33275607 | ||
| Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma | Q33275611 | ||
| Prognostic Factors in the Operative Management of Sacral Chordomas | Q33275667 | ||
| Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO) | Q33275688 | ||
| Epigenetic deregulations in chordoma | Q33275721 | ||
| The potential function of microRNA in chordomas | Q33275965 | ||
| PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation | Q33569771 | ||
| Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments | Q33810098 | ||
| The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis | Q34188723 | ||
| The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature | Q34637571 | ||
| Genistein up-regulates tumor suppressor microRNA-574-3p in prostate cancer | Q34648583 | ||
| MicroRNA-574-3p, identified by microRNA library-based functional screening, modulates tamoxifen response in breast cancer | Q34830273 | ||
| Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas | Q35070603 | ||
| CD8(+)/FOXP3(+)-ratio in osteosarcoma microenvironment separates survivors from non-survivors: a multicenter validated retrospective study | Q35506606 | ||
| Aberrant expression of microRNAs in gastric cancer and biological significance of miR-574-3p | Q36074982 | ||
| Tumor-Infiltrating Immune Cells Are Associated With Prognosis of Gastric Cancer | Q36195996 | ||
| Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis. | Q36358014 | ||
| Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization | Q36467712 | ||
| Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases | Q36597510 | ||
| Tumor-infiltrating PD1-Positive Lymphocytes and FoxP3-Positive Regulatory T Cells Predict Distant Metastatic Relapse and Survival of Clear Cell Renal Cell Carcinoma | Q36865032 | ||
| Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures | Q37422116 | ||
| The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer. | Q37564425 | ||
| Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC. | Q37637243 | ||
| Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions | Q37665660 | ||
| Mapping the face in the somatosensory brainstem | Q37697491 | ||
| The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis. | Q38355766 | ||
| The interplay of effector and regulatory T cells in cancer. | Q38366554 | ||
| Targeting immune checkpoints: New opportunity for mesothelioma treatment? | Q38598419 | ||
| A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells | Q39043650 | ||
| Biomarkers to predict prognosis and response to checkpoint inhibitors | Q39223657 | ||
| Novel oncogenic function of mesoderm development candidate 1 and its regulation by MiR-574-3p in bladder cancer cell lines | Q39426188 | ||
| Dangers of using "optimal" cutpoints in the evaluation of prognostic factors | Q40752297 | ||
| Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma. | Q41204382 | ||
| Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) Expression in epithelial-originated cancer: a meta-analysis | Q41445876 | ||
| Surgical management of primary bone tumors of the spine: validation of an approach to enhance cure and reduce local recurrence | Q42672287 | ||
| Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma | Q43788672 | ||
| S100A8+ stroma cells predict a good prognosis and inhibit aggressiveness in colorectal carcinoma | Q45510446 | ||
| Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer | Q47863345 | ||
| Emerging biomarkers for PD-1 pathway cancer therapy. | Q51275962 | ||
| P433 | issue | 2 | |
| P921 | main subject | chordoma | Q1076389 |
| spinal chordoma | Q18556214 | ||
| P304 | page(s) | 209-224 | |
| P577 | publication date | 2017-10-20 | |
| P1433 | published in | Cancer Immunology, Immunotherapy | Q5031409 |
| P1476 | title | Clinicopathologic implications of CD8+/Foxp3+ ratio and miR-574-3p/PD-L1 axis in spinal chordoma patients | |
| P478 | volume | 67 |
| Q96167187 | A four-factor immune risk score signature predicts the clinical outcome of patients with spinal chordoma |
| Q92878250 | Distinctive role of dysregulated miRNAs in chordoma cancer stem-like cell maintenance |
| Q55339993 | Key questions about the checkpoint blockade-are microRNAs an answer? |
| Q92289292 | Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma |
| Q93147363 | Recent Findings in the Regulation of Programmed Death Ligand 1 Expression |
| Q98177563 | Translational Windows in Chordoma: A Target Appraisal |
| Q98464606 | miRNA-based biomarkers, therapies, and resistance in Cancer |
Search more.